Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of Duloxetine in Patients With Osteoarthritis Knee Pain
- Conditions
- Osteoarthritis Knee Pain
- Interventions
- Drug: Duloxetine (DLX)Drug: Placebo (PLA)
- First Posted Date
- 2009-07-24
- Last Posted Date
- 2011-03-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 424
- Registration Number
- NCT00945945
- Locations
- 🇸🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Uddevalla, Sweden
A Study of LY2189102 in Patients With Type 2 Diabetes
- Conditions
- Type 2 Diabetes
- Interventions
- Drug: LY2189102Drug: Placebo
- First Posted Date
- 2009-07-20
- Last Posted Date
- 2019-09-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 106
- Registration Number
- NCT00942188
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Richmond, Virginia, United States
Effects of Teriparatide or Zoledronic Acid Treatment on Bone in Postmenopausal Osteoporotic Women
- Conditions
- Osteoporosis, Post-menopausal
- Interventions
- First Posted Date
- 2009-06-24
- Last Posted Date
- 2013-04-04
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 69
- Registration Number
- NCT00927186
- Locations
- 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sainte-Foy, Quebec, Canada
A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- First Posted Date
- 2009-06-17
- Last Posted Date
- 2014-08-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 340
- Registration Number
- NCT00922636
- Locations
- 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santurce, Puerto Rico
A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2009-06-11
- Last Posted Date
- 2019-01-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 137
- Registration Number
- NCT00918203
- Locations
- 🇨🇦
ImClone Investigational Site, Edmonton, Alberta, Canada
Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma
- Conditions
- Gastric CancerAdenocarcinoma
- Interventions
- Biological: ramucirumabDrug: PlaceboOther: Best Supportive Care (BSC)
- First Posted Date
- 2009-06-10
- Last Posted Date
- 2019-09-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 355
- Registration Number
- NCT00917384
- Locations
- 🇬🇧
ImClone Investigational Site, Wolverhampton, United Kingdom
A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer
- Conditions
- Ovarian Neoplasms
- Interventions
- Biological: OlaratumabDrug: liposomal doxorubicin
- First Posted Date
- 2009-06-04
- Last Posted Date
- 2019-09-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 125
- Registration Number
- NCT00913835
- Locations
- 🇺🇸
ImClone Investigational Site, Charlotte, North Carolina, United States
Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI)
- Conditions
- Coronary Artery Disease (CAD)
- Interventions
- First Posted Date
- 2009-05-29
- Last Posted Date
- 2012-06-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 423
- Registration Number
- NCT00910299
- Locations
- 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wuppertal, Germany
A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Biological: IMC-A12 (cixutumumab) - 10 milligrams/kilogram (mg/kg)Biological: IMC-A12 (cixutumumab) - 20 mg/kgDrug: Sorafenib
- First Posted Date
- 2009-05-21
- Last Posted Date
- 2018-06-04
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 47
- Registration Number
- NCT00906373
- Locations
- 🇺🇸
ImClone Investigational Site, Philadelphia, Pennsylvania, United States
Effect of LY2062430 on the Progression of Alzheimer's Disease
- First Posted Date
- 2009-05-20
- Last Posted Date
- 2012-09-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1000
- Registration Number
- NCT00905372
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan